Navigation Links
Aspreva's plan of arrangement with Galenica completed
Date:1/3/2008

o comply with applicable governmental regulations and standards. Readers are cautioned that the plans, intentions or expectations disclosed in any forward-looking statements and underlying assumptions may not be achieved and that they should not place undue reliance on any forward-looking statement. Actual results or events could differ materially from the plans, intentions, expectations, and assumptions expressed or implied in any forward-looking statements as a result of numerous risks, uncertainties and other factors, including those relating to: the possibility of Aspreva not being able to de-list from the NASDAQ or TSX on a timely basis.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

CONTACT: Sage J. Baker, Vice President, IR & Corporate Communications, Aspreva Pharmaceuticals, (250) 708-4270, sbaker@aspreva.com


'/>"/>
SOURCE Aspreva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The First Mega-Shelter Arrangement in Oregon Created for Major Disaster Response and Recovery
2. Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
3. Living arrangements, health and well-being: A European perspective
4. Aspreva to be Acquired by Galenica For US$915 Million
5. Aspreva obtains shareholder approval for acquisition by Galenica
6. Aspreva receives final court approval for acquisition by Galenica
7. Aspreva receives Investment Canada approval for acquisition by Galenica
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
10. Health Campaign to Protect Indonesian Children Successfully Completed
11. South Florida HIE Phase II Completed and Phase III Awarded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...nd to be effective in reducing chest pain, not ass...f patients with chest pain have no identifiable ca...e efforts by cardiologists, they continue to be se...icularly, young women seem be more prone to this c...
...that was conducted by the London School of Hygiene... pandemic across Europe, it was found that serious...tween countries existed. // The Czech Republic, It...gal were the least prepared. It is necessary that...
...d the largest outbreak of mumps over the past two ... country since 1988 // , is believed to have begun... federal officials reported yesterday that the out...ng to latest information from the U.S. Centres for...
...Queen's University and the University of Pennsylva... for drugs like Celebrex and Vioxx, administered f...otential risk of triggering a heart problem Co-aut...istry and Physiology at Queen's, and Canada Resear...
Other Medicine News:Health News:Non-Cardiac Chest Pain Can Be Treated By Hypnotherapy 2Health News:Joint Effort among Various Nations to Tackle Bird Flu 2Health News:Mumps Outbreak In The US 2Health News:Mumps Outbreak In The US 3
(Date:10/3/2008)...e newest study site, PHILADELPHIA, Oct. 3 /PRNews...ladelphia today received a contract to manage a ne...ldren,s Hospital will manage local,participation, ...ty, New,Jersey. The study is funded by the Nationa... approximately 1,000 families in Burlington,County...
(Date:10/2/2008)...f Rosetta Genomics, microRNA-based,Test, miRview(T...n Squamous non Small Cell Lung Cancer, With C...view(TM) Technology First Approved for Clinical us... Molecular Pathology Lab ... to Launch miRview(TM) Squamous Later This Ye...
(Date:10/2/2008)...stCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; T...ed on,endocrine therapy and oncology, today report... recruitment for its Phase 2 trial in ovarian canc...hormone (LHRH) agonist,linked to doxorubicin. The ...uitment was taken following recent first stage dat...
(Date:10/1/2008)...ingual lozenge) developed to be the first sleep a... when patients awaken and have difficulty .../- Transcept Pharmaceuticals,Inc., a...announced today,that it has submitted a New Drug A...tration (FDA) for its lead product candidate, Inte...
Breaking Medicine Technology:The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Dawning Technologies Inc and Medical Automation Systems Inc to Develop a Business Partnership 20850 1Dawning Technologies Inc and Medical Automation Systems Inc to Develop a Business Partnership 20850 2Haemacure Reports on Financing Progress and Second Quarter Results 20846 1Haemacure Reports on Financing Progress and Second Quarter Results 20846 2Haemacure Reports on Financing Progress and Second Quarter Results 20846 3US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 1US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 2US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 3US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 4US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 5Vaccine may double survival in patients with deadly brain tumors 20841 1Vaccine may double survival in patients with deadly brain tumors 20841 2
...rch 2007 - Cancer drug,developer Antisoma plc (LSE...tial findings from its second, confirmatory phase ..., This 30-patient trial tested an 1800 mg/m2 dose ...itaxel chemotherapy.,Investigators reported a resp... disease stabilisation, while only 7% had,progress...
...earch UK scientists in Glasgow,have devised a new ...findings in the Journal of Clinical Investigation*... Beatson Institute for Cancer,Research gave mice a...de, significantly slowing the growth of the tumour...gene called p73 that brings,about cancer cell deat...
Other Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 2Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 3
Straight shafts with 1 x 2 teeth and serrated handle with polished finish.
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands.
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 gauge shaft tapering to 23 gauge, 10 mm from tip. Overall length from rear rotation knob to tip.
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge.
Medicine Products: